REGENERON GENETICS CENTER: HOW DOES COLLABORATION DRIVE DISCOVERY?

Key Takeaways

Through more than 150 global collaborations, Regeneron Genetics Center® (RGC®) works with researchers, health systems and biobanks around the world to advance scientific discovery and better understand human health and disease.

RGC continues to expand its unique, large, representative collection of genetic and molecular data linked to health information, helping researchers uncover new insights across many diseases and populations.

Over the past decade, RGC's research has identified genetic changes linked to conditions including obesity, type 2 diabetes, heart disease, cancer and metabolic dysfunction-associated steatohepatitis (MASH), supporting the discovery and development of potential new medicines.

By tapping into data from our 150+ global collaborations, we make discoveries about human health that can expand scientific understanding and thereby accelerate our drug development process. We gather and analyze de-identified genetic and other molecular data, resulting in one of the largest, most representative genomic and multiomic databases in the world, including sequenced populations of African, Asian and Latino ancestry. Today that work is expanding beyond genetics, adding proteomics, RNA, imaging and real-world clinical data to build a comprehensive real-time picture of human biology.

By advancing a powerful shared mission, we build bridges between the global scientific community and local collaborators who aid in the discovery process.

Explore our first 10 years of collaboration, technological advancements and genetic discovery to see how we’re harnessing the power of genetics and growing range of molecular data to impact human health, now and in the future.

2026

TriNetX Collaboration

  • In 2026, we established a collaboration with TriNetX to access de-identified electronic health records of 300 million patients to drive research and product development in life sciences and digital health solutions.

FNIP1 variants associated with favorable metabolism

  • In 2026, we uncovered associations between FNIP1 variants and favorable metabolism in one million humans.

2025

3 Million Exomes Sequenced

  • In November 2025, we reached a milestone of sequencing 3 million exomes, further expanding our large-scale database.

UK Biobank Pharma Proteomics Project

  • In 2025, we launched the world’s most comprehensive study of the proteins, together with UK Biobank. The project is funded by Regeneron and 13 other biopharmaceutical companies, and RGC was selected to conduct the protein detection and sequencing process to ultimately help us understand disease progression over time.

Truveta Genome Project Collaboration (United States)

  • In 2025, we launched a collaboration with Truveta, and its collective of U.S. health systems, to conduct genetic sequencing of up to 10M de-identified patient volunteers. The results will enable the development of next-generation solutions for healthcare delivery and drug discovery and development.

2024

Validating Our Whole Exome Sequencing Approach

  • In 2024, we published in Nature Genetics, showing that the yield of genetic association signals are improved by honing in on sequencing the exome and combining it with genotyping and imputation analysis, versus conducting full whole genome sequencing.

Gen-T Brazil Collaboration (Brazil)

  • In 2024, we entered a collaboration with Gen-T — our first in South America — which built a platform that integrates genomic and de-identified health data including the Brazilian population to maximize its value for research and innovation.
 gen-t logo

2023

CHRNB2 variants linked to reduced likelihood of smoking

 Nature Genetics publication: Rare coding variants in CHRNB2 reduce the likelihood of smoking.

BRCA1 missense mutation linked to breast and ovarian cancer

  • In 2023, we collaborated with the University of Edinburgh’s Viking Genes and identified a pathogenic missense mutation in the BRCA1 gene, variant V1736A, in a founder population of Orcadians linked to cases of breast and ovarian cancer.

2M Exomes Sequenced

SuperAger Initiative

  • In 2023, we collaborated with academic, nonprofit and industry leaders to spearhead the SuperAgers Family Study — a study enrolling eligible individuals who live past age 95 with preserved cognitive capacity.
 Nature Aging publication: SuperAger Initiative: Unlocking the Genetic Potential of Exceptional Longevity.

DiscoverMe South Africa Collaboration (Durban, South Africa)

  • Since 2023, we have collaborated with the DiscoverMe initiative, we are working to create a dynamic resource of demographic, health and genetic data that can be analyzed to understand clinical disease progression and improve patient care in South Africa and beyond.

2022

Genetic associations discovered with clonal hematopoiesis of indeterminate potential (CHIP)

  • In 2022, We studied genetic data from over 620,000 individuals and identified novel risk loci and phenotypic association with clonal hematopoiesis of indeterminate potential (CHIP), an aging-related blood condition that has been associated with an increased risk of blood cancers, cytopenias and cardiovascular disease (CVD).

Mutation in INHBE associated with protection from type 2 diabetes

 Nature Communications publication: Multi- ancestry exome sequencing reveals INHBE protein- truncating variants associated with favorable fat distribution and liver-adipose interplays in energy storage.

CIDEB mutations linked to reduced risk of metabolic dysfunction-associated steatohepatitis

  • In 2022, by sequencing over 540,000 exomes, we identified rare mutations in the CIDEB gene occurring in ~1/700 people. Those with one mutated copy of CIDEB had a 53% lower risk for metabolic dysfunction-associated steatohepatitis (MASH).

    Hear from the team who helped uncover the CIDEB mutation:

 Video of Regeneron Genetic Center researchers sharing how they discovered the CIDEB mutations linked to reduced risk of metabolic associated steatohepatitis.

Levels of ACE2 receptor may influence COVID-19 risk

Mexico City Prospective Study (MCPS)/National Autonomous University of Mexico Collaboration (UNAM)

  • In 2022, to reduce the genomic diversity gap, we joined the Mexico City Prospective Study (MCPS) research team, comprising the National Autonomous University of Mexico (UNAM) in Mexico City and the Nuffield Department of Population Health in Oxford, to conduct the most extensive sequencing study in individuals of non-European ancestry to date.

    Summary data are accessible to the scientific community to facilitate future genomic research via the MCPS Variant Browser.

Mt. Sinai School of Medicine Collaboration (New York, United States)

  • In 2022, we conducted our largest Regeneron-supported sequencing effort at the time to create a genetics database that allows us to assess the value of genetics-based medicine.

2021

Rare mutation in GPR75 gene associated with reduced risk for obesity

  • In 2021, our scientists discovered a rare genetic mutation in the GPR75 gene that is associated with reduced risk for obesity.

Hear Aris Baras, M.D. describe how RGC discovered GPR75.

Hear Manuel Ferreira, Ph.D. share how looking at data at a larger scale aided in the discovery of GPR75.

Hear Luca Lotta, M.D., Ph.D. detail how the discovery of GPR75 can reshape the way we address obesity.

B4GALT1 variant linked to lower LDL cholesterol and fibrinogen levels

  • In 2021, in collaboration with University of Maryland Medical School, we researched the Lancaster, Pennsylvania Amish community and discovered a gene variant, B4GALT1, linked to lower LDL cholesterol and fibrinogen levels.
 Science publication: Genetic and functional evidence links a missense variant in B4GALT1 to lower LDL and fibrinogen.

Analysis of 454K+ UK Biobank participants

In 2021, through the exome sequencing and analysis of more than 450,000 UK Biobank participants, we identified the following:

  • An association between a burden of protein-altering variants in MAP3K15 and lower levels of hemoglobin A1c, serum glucose and protection from type 2 diabetes
  • The SLC9A3R gene, which has a novel risk-lowering association for hypertension

Advent Aurora Health System Collaboration (Wisconsin, United States)

  • In 2021, we launched a large-scale initiative to sequence 267,000 consented volunteer participants in the Advent Aurora Health System, linking genomic data to de-identified electronic medical record (EMR) data to enable large-scale gene discovery.

South Asia Biobank Collaboration (London, England)

  • Since 2021, in collaboration with Imperial College London, we have been investigating the underlying genetic mechanisms that support health and disease progression in volunteer participants of South Asian ancestry.

2020

KCNQ1 missense variation associated with long QT Syndrome type 1

  • In 2020, working with the Amish Research Clinic (ARC), we identified a missense variant in the KCNQ1 gene, present in 1/45 Amish individuals. The KCNQ1 gene is associated with long QT syndrome type 1, which can lead to syncope and sudden cardiac death.

1M Exomes Sequenced by RGC

  • In February 2020, we sequenced our millionth exome — creating a robust and diverse database to aid in genetic discovery and serve as a resource for the scientific community.
 Video of Suganthi Balasubramanian explaining Regeneron Genetic Center®’s 1M exome project.

Colorado Center for Personalized Medicine Collaboration (Colorado, United States)

  • In 2020, we launched a large-scale initiative to sequence 150,000 consented volunteer participants in the Colorado Center for Personalized Medicine health network, linking genomic data to de-identified electronic medical record (EMR) data to enable large-scale gene discovery.

Université de Paris Collaboration (Paris, France)

  • Since 2020, in collaboration with the Université de Paris, we have been investigating the underlying genetic mechanisms that support activation of the immune response in A29-positive individuals.

Rambam Health Care Campus Collaboration (Haifa, Israel)

  • In 2019, we launched the Genetics Institute of Rambam Health Care Campus, we identify novel genes for rare undiagnosed disorders with Mendelian inheritance.

2019

Mayo Clinic Biobank Collaboration (Minnesota, United States)

  • Since 2019, we launched a large-scale initiative to sequence 250,000 consented volunteer participants in the Mayo Clinic health network, linking genomic data to de-identified electronic medical record (EMR) data to enable large-scale gene discovery.

Bangladesh Longitudinal Investigation of Emerging Vascular Events (BELIEVE) Study (Cambridge, England)

  • Since 2019, in collaboration with University of Cambridge, we have been investigating the burden of cardiovascular and other chronic non-communicable diseases.

2018

Mutation in HSD17B13 protects from liver disease

  • In 2018, we discovered the first genetic superpower in chronic liver disease, a mutation in the HSD17B13 gene that protects from liver disease.

Taichung Veterans General Hospital Collaboration (Taiwan)

  • Since 2018, in collaboration with Taichung Veterans General Hospital, we have been linking genetics and longitudinal electronic medical record (EMR) data from 100,000 patients in the health system.

2017

Protective variant in ANGPTL3 reduces risk of heart disease and diabetes

  • In 2017, we discovered that inhibition of the ANGPTL3 gene in humans and mice is associated with decreased levels of all three major lipid fractions and protection from atherosclerotic cardiovascular disease.

UK Biobank Collaboration (Stockport, England)

  • Since 2017, we have partnered with the UK Biobank to whole-exome sequence hundreds of thousands of volunteers and pair that data with detailed, de-identified medical and health records to accelerate research goals.

    Hear how our collaboration with UK BioBank helps accelerate discoveries and find determinants of disease.

 Animated video highlighting Regeneron Genetic Center®’s collaboration with UK Biobank.

2016

Lund University Collaboration (Sweden)

  • In 2016, our team’s collaboration with Lund University has allowed us to better understand genetic effects of cardiometabolic diseases.

    Learn about the benefits of open collaboration:

2015

Penn Medicine Biobank Initiative

  • In 2015, we launched a large-scale initiative to sequence 130,000 consented volunteer participants in the Penn Medicine Biobank, linking genomic data to de-identified electronic medical record (EMR) data to enable large-scale gene discovery in the Philadelphia population.

2014

Illumina Sequencer Collaboration

  • In January of 2014, we announced a partnership with Illumina, that allows us to use the HiSeq 2500 System and Infinium HumanOmniExpressExome BeadChip array to analyze patient data.
 Illumina logo.

Geisinger Health Systems Collaboration (Pennsylvania, United States)

  • In 2014, as one of our first, crucial collaborations, we launched a large-scale initiative to sequence 100,000 consented participants with Geisinger in 2014, linking genomic data to de-identified electronic medical record (EMR) data to enable large-scale gene discovery at an unprecedented scale.
 Geisinger logo.

Amish Research Clinic and Clinic for Special Children Collaboration (Maryland, United States)

  • Since 2014, in collaboration with the University of Maryland Baltimore, we’re studying volunteer participants at the Amish Research Clinic and a variety of complex diseases and traits including cardiovascular disease, hyperlipidemia, diabetes, osteoporosis and bone health, pulmonary function, longevity, and general wellness. In addition, we’re collaborating with the Amish Clinic for Special Children to study the genetic basis of early-onset and familial forms of pediatric disorders in Amish and Mennonite populations.

Frequently Asked Questions

Regeneron Genetics Center (RGC) is Regeneron's human genetics and molecular data research organization. It studies genetic, molecular and health data from millions of volunteer participants to better understand how diseases develop and to help discover potential prevention and treatment approaches.

RGC studies how genes, proteins and other biological factors are connected to health and disease. By combining these data with health records and advanced technology, researchers can identify genetic changes that may influence disease risk, progression and treatment.

Genetic research helps scientists better understand the biological causes of disease. These insights can identify new drug targets, improve the understanding of existing diseases and support the development of potential new medicines that may address unmet patient needs.

Working with research partners around the world helps RGC study data from people with different backgrounds and health experiences. This broader understanding of human biology can improve scientific discoveries and help researchers learn more about diseases that affect diverse populations.

RGC has built a unique, large, representative dataset of genetic and molecular data linked to health information through collaborations with health systems, biobanks and research organizations around the world. This large-scale resource helps researchers uncover new insights into human health and disease while supporting the discovery of potential new medicines.